Compare TRX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | ALT |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.0M | 415.3M |
| IPO Year | 2002 | 2005 |
| Metric | TRX | ALT |
|---|---|---|
| Price | $1.77 | $4.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.70 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 5.9M | 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | $73.52 | N/A |
| Revenue Next Year | $109.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $2.91 |
| 52 Week High | $2.80 | $7.73 |
| Indicator | TRX | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 41.40 |
| Support Level | $0.31 | $4.27 |
| Resistance Level | $1.87 | $4.53 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 42.39 | 32.64 |
TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.